Drug Trial Radar · NCT07712757
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
May 2029
Study completion Mar 2032
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy.
Conditions
- Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation
- Astrocytoma IDH Mutant Grade 2
- Oligodendroglioma
- Oligodendroglioma IDH-mutant and 1p/19q-codeleted
- IDH-mutant Gliomas
Interventions
SafusidenibDrug
Safusidenib administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs.
PlaceboDrug
Placebo administered twice daily as a single agent dosed orally on Days 1 through 28 of a 28-day cycle. Participants may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0Time frame: From the date of randomization until the date of first documented disease progression, approximately 30 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.